ストックスクリーナーアプリを入手
28.45
5.48%
-1.65
アフターアワーズ：
28.45
前日終値:
$30.10
開ける：
$30.16
24時間の取引高:
653.15K
Relative Volume:
1.21
時価総額：
$1.40B
収益：
-
当期純損益:
$-166.31M
株価収益率:
-6.3786
EPS:
-4.4602
ネットキャッシュフロー:
$-160.59M
1週間 パフォーマンス:
-1.56%
1か月 パフォーマンス:
-9.25%
6か月 パフォーマンス:
+25.05%
1年 パフォーマンス:
+65.70%
1日の値動き範囲:
$28.43
$30.55
1週間の範囲:
$28.20
$31.49
52週間の値動き範囲:
$17.00
$35.83
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Compare AVBP vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
28.45 | 1.40B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-12-10 | 開始されました | BTIG Research | Buy |
| 2025-11-25 | 開始されました | Truist | Buy |
| 2025-07-10 | 再開されました | Goldman | Buy |
| 2025-03-20 | 開始されました | B. Riley Securities | Buy |
| 2025-03-10 | 開始されました | Guggenheim | Buy |
| 2024-07-22 | 開始されました | Oppenheimer | Outperform |
| 2024-04-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-02-20 | 開始されました | Citigroup | Buy |
| 2024-02-20 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | Jefferies | Buy |
すべてを表示
Arrivent Biopharma Inc (AVBP) 最新ニュース
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cantor Fitzgerald reiterates Overweight on ArriVent stock By Investing.com - Investing.com Nigeria
ArriVent BioPharma (AVBP) Stock Price, News & Analysis - MarketBeat
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Explosive 57.62% Upside Potential Fuels Investor Interest - DirectorsTalk Interviews
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating - Moomoo
Understanding the Setup: (AVBP) and Scalable Risk - Stock Traders Daily
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ArriVent’s ARR-002 Moves Forward in Early Ovarian and Endometrial Cancer Study - TipRanks
ArriVent BioPharma: Firmonertinib Delay Strengthens The Upside Case (NASDAQ:AVBP) - Seeking Alpha
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - qz.com
Why Did ArriVent BioPharma (AVBP) Move Today? - sahmcapital.com
ArriVent (AVBP) Trading: Posts a 2.95% Loss to $28.26 in the Current Update; Levels: Price Remains Between $26.85 Support and $29.67 ResistanceIV Spike - vinanet.vn
109,328 Shares in ArriVent BioPharma, Inc. $AVBP Acquired by E Fund Management Co. Ltd. - MarketBeat
We Think ArriVent BioPharma (NASDAQ:AVBP) Can Afford To Drive Business Growth - Moomoo
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash - MyChesCo
HC Wainwright Issues Pessimistic Forecast for AVBP Earnings - MarketBeat
What is HC Wainwright's Estimate for AVBP FY2027 Earnings? - MarketBeat
H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47 - Moomoo
ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal - Sahm
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook - Investing.com
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $47.00 - MarketBeat
H.C. Wainwright raises ArriVent BioPharma price target on trial outlook By Investing.com - Investing.com Canada
ArriVent Biopharma price target lowered to $40 from $43 at Citi - TipRanks
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Technical Reactions to AVBP Trends in Macro Strategies - Stock Traders Daily
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50 - Moomoo
ArriVent hands Allist Greater China rights to MUC16/NaPi2b ADC - AllSci
ArriVent BioPharma (NASDAQ:AVBP) Receives "Buy" Rating from Guggenheim - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 4.7% Following Weak Earnings - MarketBeat
A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50 - Moomoo
ArriVent BioPharma: Pipeline Progress and Funding Strength Support Buy Rating and Unchanged $42 Price Target - TipRanks
ArriVent BioPharma's (AVBP) "Buy" Rating Reaffirmed at BTIG Research - MarketBeat
Tema ETFs LLC Invests $1.98 Million in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Dimensional Fund Advisors LP Has $2.92 Million Stock Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma Reports Second Quarter 2026 Financial Results - The Manila Times
AVBP SWOT Analysis: Financial Strength and Growth Potential Reve - GuruFocus
ArriVent BioPharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
ArriVent BioPharma (NASDAQ:AVBP) Posts Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
ArriVent inks China partnership for ARR-002 development - TipRanks
AVBP: Firmonertinib and novel ADCs show strong clinical progress, with major milestones ahead in 2026 - TradingView
ArriVent BioPharma (NASDAQ: AVBP) details $93M loss and $373M cash buffer - Stock Titan
ArriVent BioPharma reports $49.9 million Q2 net loss - Quiver Quantitative
ArriVent Expects Firmonertinib Lung Cancer Trial Data in 2H 2026 - Stock Titan
ArriVent BioPharma (AVBP) Edges Higher, Holding Key Support at $29.44Jelly Roll Trade - dars.gov.et
ArriVent BioPharma (AVBP) Eases 0.55% to $30.84 as Shares Remain Range-BoundBull Flag - vinanet.vn
ArriVent BioPharma (AVBP) Expected to Release Quarterly Earnings on Friday - MarketBeat
Trading the Move, Not the Narrative: (AVBP) Edition - Stock Traders Daily
ArriVent BioPharma (AVBP) Surges 6.24% to $31.49 – Biotech Momentum IntensifiesGEX Level - vinanet.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vivo Capital LLC Takes $20.44 Million Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
141,814 Shares in ArriVent BioPharma, Inc. $AVBP Bought by ADAR1 Capital Management LLC - MarketBeat
Arrivent Biopharma Inc (AVBP) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):